Cooley advised ViewPoint Therapeutics on closing its $35 million Series B funding round led by TPG’s new $2 billion social impact fund, The Rise Fund. The…
ViewPoint Therapeutics’ $35 Million Series B Round Funding
Cooley advised ViewPoint Therapeutics on closing its $35 million Series B funding round led by TPG’s new $2 billion social impact fund, The Rise Fund. The…